In a heart-wrenching turn of events, a New Jersey-based animal health technology firm, Zoetis Inc., faces a lawsuit following the tragic death of an 11-year-old dog due to a misdiagnosis linked to its artificial intelligence diagnostic tool. The Columbia Veterinary Hospital in The Dalles, Oregon, filed the complaint, seeking a minimum of $50,000 in damages, alleging that the company’s negligence and deceptive practices contributed to the loss of a beloved pet.
Misdiagnosis by AI Tool
In October 2025, veterinarians at Columbia Veterinary Hospital used Zoetis’ Vetscan Imagyst system to assess tissue samples from a Belgian Tervuren, who presented with a rapidly enlarging mass on its neck. Despite the AI identifying characteristics typically associated with cancerous growths, it ultimately misclassified the tumour as an inflammatory lesion. This erroneous assessment led to a surgical procedure to remove the mass, based on the faulty AI analysis.
The grim reality emerged when further examination by the Oregon State University Veterinary Diagnostic Lab confirmed that the mass was, in fact, an aggressive form of cancer. The misdiagnosis proved fatal, as the initial surgery failed to remove all malignant tissue, necessitating a second invasive procedure. Unfortunately, the dog succumbed to complications from this follow-up surgery.
Allegations of Deceptive Practices
The lawsuit paints a disturbing picture of corporate negligence. According to the court documents, Columbia Veterinary Hospital purchased the Vetscan Imagyst system in 2024, lured by assurances that it offered expert-level diagnostics. The complaint alleges that Zoetis falsely marketed the technology as “the world’s most capable veterinary AI analyzer,” while neglecting to disclose its operational limitations and the potential for misdiagnosis.
The hospital argues that the need for a second surgery directly resulted from the AI’s failure to accurately identify the tumour as cancerous. “The patient’s death resulted directly from the need for a second invasive surgical procedure,” the lawsuit states, highlighting the direct link between the AI’s misjudgment and the tragic outcome.
Acknowledgment of Errors
Further compounding the gravity of the situation, the complaint alleges that Zoetis altered the initial diagnostic report after the clinic flagged the error. Following this, a conference call was arranged between the clinic staff and Zoetis representatives, during which the latter reportedly apologised and admitted their responsibility. They also revealed that similar misidentifications had occurred with other clients using the Imagyst platform.
As the lawsuit unfolds, it raises significant questions about the reliability of AI in medical diagnostics, particularly when the stakes are as high as the health and lives of beloved pets.
Industry Implications
The repercussions of this case extend beyond a single tragic incident. The reliance on AI technology in veterinary medicine is growing, and this lawsuit underscores the urgent need for transparency and accountability within the industry. As consumers increasingly turn to innovative diagnostic tools, they must also be informed about the potential risks and limitations that accompany such technologies.
Why it Matters
This case serves as a stark reminder of the heavy toll that comes with technological advancement in veterinary medicine. The tragic loss of a cherished pet highlights the critical need for accuracy and trust in diagnostic tools. As AI continues to permeate healthcare, the implications stretch beyond individual cases, compelling a broader conversation about ethics, accountability, and the emotional consequences for pet owners who place their trust in these systems. The outcome of this lawsuit could set a precedent that shapes the future of veterinary diagnostics and the role of AI within it.
